Invesco’s BioAtla BCAB Stock Holding History

Invesco’s Portfolio BCAB Stock Details BCAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-408	Closed	-$70.1K	–	3882
2024 Q1	$70.1K	Sell	408 -15	-4%	-$1.86K	﹤0.01%	3775
2023 Q4	$52K	Buy	423 +66	+18%	+$5.72K	﹤0.01%	3747
2023 Q3	$30.4K	Buy	357 +1	+0.3%	+$127	﹤0.01%	3829
2023 Q2	$53.4K	Buy	+356	New	+$61.2K	﹤0.01%	3811

Other funds holding BCAB

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

SAM

Scion Asset Management Saratoga, California $1.38B AUM 43.96% 1-Year Est. Return

Invesco's BCAB Position: Q2 2024 in Review

Invesco sold out of BioAtla (BCAB) in Q2 2024, closing a stake of 408 shares — an estimated $70.1K sold.

Invesco first reported a position in BCAB in Q2 2023 and held it in 4 quarters. The position peaked at $70.1K in Q1 2024. 80 funds tracked by Wall St. Rank hold BCAB as of Q2 2024.

Invesco reported no remaining BioAtla position as of Q2 2024 after selling out during the quarter.
Invesco sold 408 BioAtla shares in Q2 2024, an estimated $70.1K.
Invesco first reported a position in BioAtla in Q2 2023 and held it in 4 quarters.
Invesco's BioAtla position peaked at $70.1K in Q1 2024.
80 funds tracked by Wall St. Rank held BioAtla as of Q2 2024.

Based on Invesco's 13F filing for Q2 2024, filed 13 Aug 2024.